Cash balance had improved by $2.1million to $15.8mill at the end...

Cash balance had improved by $2.1million to $15.8mill at the end of January 2022. Though, I suspect the sugar hit of RATs will wane over the next FY. We'll probably see seasonal spikes on sales, coupled with an immediate increase when WA and NZ open.

HIV sales need to move from small pharmacy channels to contracts with big national retailers. I would expect the company to make significant leaps in this space being the first and ONLY mover at this stage with TGA approval. If they can't capitalise on this opportunity then they simply dont have the right people to build/optimise sales. Finally, the mark up on the Viatris LMIC program is very small, but I'd be remiss if I didn't acknowledge it helps build global branding.

Cash position should be well improved by Q3 results, but I agree, we may see a capital raise in the next 12 to 24 months if HIV and OEM sales don't fill a retreating void left by subsiding or a more rational stabilising of consumer demand for RAT.